Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

13.27 -0.46 (-3.32%)
Streaming Delayed Price Updated: 11:31 AM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 262,843
Open 13.62
Bid (Size) 13.26 (100)
Ask (Size) 13.27 (200)
Prev. Close 13.72
Today's Range 13.27 - 13.81
52wk Range 7.020 - 15.42
Shares Outstanding 1,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Amneal Reports First Quarter 2026 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal (AMRX) Q3 2025 Earnings Call Transcript ↗
Amneal (AMRX) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
+4.8%
+4.8%
1 Month
+7.7%
+7.7%
3 Month
-10.2%
-10.2%
6 Month
+13.8%
+13.8%
1 Year
+83.7%
+83.7%

More News

Read More
News headline image
Amneal (AMRX) Q2 2025 Earnings Transcript ↗
Via The Motley Fool
Topics Supply Chain
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Q4 2025 Earnings Beat on Strong Profitability ↗
Via Chartmill
Topics Earnings
News headline image
1 Value Stock to Target This Week and 2 Facing Challenges
Via StockStory
News headline image
Amneal (AMRX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Amneal (AMRX) Q1 Earnings Report Preview: What To Look For
Via StockStory
News headline image
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
From Kashiv BioSciences, LLC
Via Business Wire
News headline image
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know
Via StockStory
Topics Economy
News headline image
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
2 Cash-Producing Stocks to Research Further and 1 We Brush Off
Via StockStory
News headline image
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 of Wall Street’s Favorite Stocks We Steer Clear Of
Via StockStory
News headline image
Amneal to Report First Quarter 2026 Results on May 1, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 Small-Cap Stocks Walking a Fine Line
Via StockStory
News headline image
Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
News headline image
3 Value Stocks We’re Skeptical Of
Via StockStory
News headline image
Amneal to Participate in Upcoming Investor Conference
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Why Amneal (AMRX) Stock Is Trading Lower Today
Via StockStory
News headline image
Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations
Via StockStory

Frequently Asked Questions

Is Amneal Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Amneal Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Amneal Pharmaceuticals, Inc. - Class A Common Stock trade on?
Amneal Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock is AMRX on the Nasdaq Stock Market
What is the current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 13.27
When was Amneal Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Amneal Pharmaceuticals, Inc. - Class A Common Stock was at 05/08/26 11:31 AM ET
What is the market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 13.27K
How many shares of Amneal Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Amneal Pharmaceuticals, Inc. - Class A Common Stock has 13K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.